Current and Future Pharmacologic Options for the Management of Patients Unable to Achieve Low-Density Lipoprotein-Cholesterol Goals with Statins

@article{Harchaoui2008CurrentAF,
  title={Current and Future Pharmacologic Options for the Management of Patients Unable to Achieve Low-Density Lipoprotein-Cholesterol Goals with Statins},
  author={Karim El Harchaoui and Fatima Akdim and Erik S. G. Stroes and Mieke D. Trip and John J. P. Kastelein},
  journal={American Journal of Cardiovascular Drugs},
  year={2008},
  volume={8},
  pages={233-242}
}
Low-density lipoprotein-cholesterol (LDL-C) lowering is the mainstay of the current treatment guidelines in the management of cardiovascular risk. HMG-CoA reductase inhibitors (statins) are currently the most effective LDL-C-lowering drugs. However, a substantial number of patients do not reach treatment targets with statins. Therefore, an unmet medical need exists for lipid-lowering drugs with novel mechanisms of action to reach the recommended cholesterol target levels, either by monotherapy… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-7 OF 7 CITATIONS